December 2, 2024 11:00 AM EST : The Citizens JMP Hematology and Oncology Summit Post author:Allogene Therapeutics Events Post published:December 2, 2024 Post category:Uncategorized Continue ReadingDecember 2, 2024 11:00 AM EST : The Citizens JMP Hematology and Oncology Summit
November 20, 2024 6:30 AM EST : Jefferies London Healthcare Conference Post author:Allogene Therapeutics Events Post published:November 20, 2024 Post category:Uncategorized Continue ReadingNovember 20, 2024 6:30 AM EST : Jefferies London Healthcare Conference
November 18, 2024 8:35 AM EST : Stifel 2024 Healthcare Conference Post author:Allogene Therapeutics Events Post published:November 18, 2024 Post category:Uncategorized Continue ReadingNovember 18, 2024 8:35 AM EST : Stifel 2024 Healthcare Conference
November 7, 2024 5:00 PM EST : Allogene Therapeutics Third Quarter 2024 Conference Call Post author:Allogene Therapeutics Events Post published:November 7, 2024 Post category:Uncategorized Continue ReadingNovember 7, 2024 5:00 PM EST : Allogene Therapeutics Third Quarter 2024 Conference Call
October 1, 2024 1:00 PM EDT : Goldman Sachs Cell Therapy Day Conference Post author:Allogene Therapeutics Events Post published:October 1, 2024 Post category:Uncategorized Continue ReadingOctober 1, 2024 1:00 PM EDT : Goldman Sachs Cell Therapy Day Conference
September 11, 2024 10:15 AM EDT : Baird 2024 Global Healthcare Conference Post author:Allogene Therapeutics Events Post published:September 11, 2024 Post category:Uncategorized Continue ReadingSeptember 11, 2024 10:15 AM EDT : Baird 2024 Global Healthcare Conference
August 13, 2024 10:00 AM EDT : Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase Post author:Allogene Therapeutics Events Post published:August 13, 2024 Post category:Uncategorized Continue ReadingAugust 13, 2024 10:00 AM EDT : Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy Post author:andrewkaretas Post published:July 15, 2024 Post category:Uncategorized Continue ReadingALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy
FT US Pharma and Biotech Summit Post author:andrewkaretas Post published:June 12, 2024 Post category:Perspectives/Uncategorized Continue ReadingFT US Pharma and Biotech Summit
Test Post author:andrewkaretas Post published:October 5, 2021 Post category:Uncategorized Continue ReadingTest
